Skip to main content

Advertisement

Table 1 Summary of patient characteristics for the study cohort

From: A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

  Study cohort
  n %
Randomised treatment
 E-CMF 1156 19
 CMF 1149 19
 EC-T 1773 28
 EC-TG 1769 28
 T-EC 200 3
 TG-EC 201 3
Age, years
 ≤ 50 3606 58
 > 50 2642 42
ER status
 Negative 2551 41
 Positive 3591 57
 Missing 106 2
pGR status
 Negative 2463 39
 Positive 2652 43
 Missing 1133 18
HER2 status
 Negative 3760 60
 Positive 1034 17
 Missing 1454 23
Nodal status
 Negative 1366 22
 1–3 positive 2383 38
 Clinically negative, neoadjuvant 409 7
 Clinically positive, neoadjuvant 403 6
 4+ positive 1687 27
Breast cancer-specific survival
 Breast cancer related deaths 1335 21
 Deaths due to other cause 148 2
 Alive 4765 77
Relapse-free survival
 Events 1888 30
 Censored 4360 70
Triple negative status
 No (ER+ and HER2) 2321 37
 Yes (ER, PGR or unknown, and HER2) 1242 20
 Missing 2685 43
ECOG performance status
 0 5232 84
 ≥ 1 683 11
 Missing 333 5
Tumour size, mm
 0–20 2195 35
 21–50 3375 54
 > 50 475 8
 Missing 203 3
Tumour grade
 1 146 2
 2 2206 35
 3 3654 59
 Missing 242 4
Menopausal status
 Pre/peri 3480 56
 Post 2200 35
 Missing 568 9
BMI
 Underweight (<18.5) 69 1
 Healthy weight (18.5 to <25) 2503 40
 Overweight (25 to <30) 2088 33
 Obese (≥30) 1469 24
  1. ER Estrogen receptor; pGR Progesterone receptor; HER2 Human epidermal growth factor receptor; ECOG Eastern Co-operative Oncology Group; BMI Body mass index; E Epirubicin; C Cyclophosphamide; M Methotrexate; F 5-fluouroucil; T Paclitaxel; G Gemcitabine